arrow
M

Mark Gorman

Mayo Clinic
H指数:59
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal stability of dietary intake patterns in pediatric-onset multiple sclerosis: A multicenter prospective cohort study

儿科发病多发性硬化症患者膳食摄入模式的纵向稳定性:一项多中心前瞻性队列研究

2026-09-010
PRE
Neurological manifestations and vasculopathy in PLCG2–associated antibody deficiency and immune dysregulation (APLAID): a case series

PLCG2相关抗体缺陷和免疫失调(APLAID)中的神经系统表现和血管病变:一个病例系列

2026-08-290
OAAI
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis

从口服或静脉输注改为注射型疾病修正疗法在儿童多发性硬化中的真实世界有效性

2025-11-060
OAAI
Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis

表观遗传年龄与儿童期发病多发性硬化的端粒长度相关性

2025-11-060
OA
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry

评估使用Avonex或Plegridy治疗儿童多发性硬化患者的疗效结局:基于USNPMSC注册研究

2025-09-010
PRE
Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis

抗N-甲基-d天冬氨酸受体脑炎患儿的孤立精神症状

2024-10-010
PRE
Distinct plasma lipids predict axonal injury and multiple sclerosis activity
2024-09-120
PRE
Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis: A Case-Control Study
2024-09-010
OA
Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease
2024-07-042
PRE
Gene-environment interactions: Epstein-Barr virus infection and risk of pediatric-onset multiple sclerosis
2024-02-091
OA
Short-chain fatty acid producers in the gut are associated with pediatric multiple sclerosis onset
2023-11-135
OA
Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments
2023-08-019
PRE
Longitudinal Cognitive Screening Findings in Pediatric MS vs. Pediatric Controls and Adult MS in a Multi-center Cohort
2023-04-250
PRE
Real-world effectiveness of switching treatment after initial platform injectable disease-modifying therapies in pediatric multiple sclerosis in the US
2023-04-250
PRE